Author | Editors: Sandra Swain, MD

Articles

Treatment of Estrogen Deficiency Symptoms in Women Surviving Breast Cancer, Part 6

June 01, 1999

Problem: Several million women worldwide have survived breast cancer but are currently advised against the use of estrogen for the management of menopausal symptoms and for the prevention of early cardiovascular death and osteoporosis.

Treatment of Estrogen Deficiency Symptoms in Women Surviving Breast Cancer, Part 5

May 01, 1999

There are several million breast cancer survivors worldwide. In the United States, 180,000 women were

Treatment of Estrogen Deficiency Symptoms in Women Surviving Breast Cancer, Part 4

April 01, 1999

There are several million breast cancer survivors worldwide. In the United States, 180,000 women were diagnosed

Treatment of Estrogen Deficiency Symptoms in Women Surviving Breast Cancer, Part 3

March 01, 1999

There are several million breast cancer survivors worldwide. In the United States, 180,000 women were diagnosed with breast cancer in 1997, and approximately 97,000 of these women have an extremely low chance of a suffering a recurrence of their cancer. With an average age at diagnosis of 60 years and a 25-year expected duration of survival, the current number of breast cancer survivors in the United States may approach 2.5 million women. Since breast cancer is now being detected at an earlier stage than previously and since adjuvant chemotherapy may cause ovarian failure, an increasing number of women are becoming postmenopausal at a younger age after breast cancer treatment. This conference was convened in September 1997 to consider how menopausal breast cancer survivors should be treated at the present time and what future studies are needed to develop improved therapeutic strategies. A total of 47 breast cancer experts and 13 patient advocates participated. The proceedings of the conference are being published in six installments in successive issues of oncology. This third part focuses on the prevention of osteoporosis and the cardiovascular effects of estrogens and antiestrogens. [ONCOLOGY 13(3):397-432, 1999]